Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan L Cohn

Showing results (131-140 of 183) with videos related to

Pageof 19
Sort By:
Journal of Pain and Symptom Management|May 4, 2020
Racial and Ethnic Differences in Communication and Care for Children With Advanced CancerJennifer W Mack, Hajime Uno, Clare J Twist, et al.
Pediatric Blood & Cancer|December 19, 2013
Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621)Elizabeth Fox, Yael P Mosse', Holly M Meany, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force reportTom Monclair, Garrett M Brodeur, Peter F Ambros, et al.
The New England Journal of Medicine|November 25, 2005
Chromosome 1p and 11q deletions and outcome in neuroblastomaEdward F Attiyeh, Wendy B London, Yael P Mossé, et al.
Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society|September 11, 2014
Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology GroupRisa Teshiba, Shinya Kawano, Larry L Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumorsElizabeth Fox, John M Maris, Brigitte C Widemann, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2010
Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group ProjectVeronica Moroz, David Machin, Andreas Faldum, et al.
The New England Journal of Medicine|October 1, 2010
Outcome after reduced chemotherapy for intermediate-risk neuroblastomaDavid L Baker, Mary L Schmidt, Susan L Cohn, et al.
Cancer|October 5, 2019
Unrealistic parental expectations for cure in poor-prognosis childhood cancerJennifer W Mack, Angel M Cronin, Hajime Uno, et al.
Cancer|December 15, 2023
Factors influencing parents' choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi-site longitudinal survey studyErica C Kaye, Jesse Smith, Yiwang Zhou, et al.
Pageof 19

Showing results (131-140 of 183) with videos related to

Sort By:
Pageof 19
Journal of Pain and Symptom Management|May 4, 2020
Racial and Ethnic Differences in Communication and Care for Children With Advanced CancerJennifer W Mack, Hajime Uno, Clare J Twist, et al.
Pediatric Blood & Cancer|December 19, 2013
Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621)Elizabeth Fox, Yael P Mosse', Holly M Meany, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force reportTom Monclair, Garrett M Brodeur, Peter F Ambros, et al.
The New England Journal of Medicine|November 25, 2005
Chromosome 1p and 11q deletions and outcome in neuroblastomaEdward F Attiyeh, Wendy B London, Yael P Mossé, et al.
Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society|September 11, 2014
Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology GroupRisa Teshiba, Shinya Kawano, Larry L Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumorsElizabeth Fox, John M Maris, Brigitte C Widemann, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2010
Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group ProjectVeronica Moroz, David Machin, Andreas Faldum, et al.
The New England Journal of Medicine|October 1, 2010
Outcome after reduced chemotherapy for intermediate-risk neuroblastomaDavid L Baker, Mary L Schmidt, Susan L Cohn, et al.
Cancer|October 5, 2019
Unrealistic parental expectations for cure in poor-prognosis childhood cancerJennifer W Mack, Angel M Cronin, Hajime Uno, et al.
Cancer|December 15, 2023
Factors influencing parents' choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi-site longitudinal survey studyErica C Kaye, Jesse Smith, Yiwang Zhou, et al.
Pageof 19